ReViral, a London, UK-based antiviral drug discovery and development company, focused on diseases caused by the Respiratory Syncytial Virus (RSV), completed a US$55m Series B financing.
The financing was led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings A/S, with additional new investment from Perceptive Advisors. Existing investors Andera Partners, OrbiMed and Brace Pharma Capital also participated in the fundraise. In conjunction with the financing, representatives of New Leaf Ventures and Novo Ventures will be joining the ReViral Board of Directors.
Led by Dr Ken Powell, Executive Chairman, ReViral is an antiviral drug discovery and development company focused on novel antiviral treatments for diseases caused by the respiratory syncytial virus (RSV).
Founded in 2011, ReViral has developed a novel antiviral program targeting RSV fusion with potent, orally bioavailable inhibitors with drug-like characteristics and pharmacokinetic properties offering versatility in route of administration.
The company intends to use the funds to progress its lead drug candidate (RV521), an orally bioavailable potential treatment for RSV infections, into Phase IIa paediatric and adult trials, and to continue the development of a novel series of antiviral inhibitors targeting RSV replication.
RV521 is soon expected to enter an international multicentre Phase IIa paediatric trial. This study will be followed by additional trials in adult stem cell transplant patients.